Veozah, an oral once-daily medication, is the first FDA-approved NK3 receptor antagonist for hot flashes, a common symptom of menopause that can affect health and quality of life.
https://www.pharmalive.com/wp-content/uploads/2022/02/FDA-Ad-Com-Comes-Down-Hard-on-Avenues-IV-Tramadol-BioSpace-2-16-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-05-15 09:13:372023-05-15 09:15:56Astellas wins FDA approval for hot flash treatment in menopausal women
